FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

Grail's Galleri test detects signals for 50 types of cancer from a single blood sample. An FDA advisory committee is reviewing the test for regulatory clearance. A clinical study of the test did not demonstrate detection capability for later-stage cancers. Medicare coverage decisions typically follow FDA approval if the agency authorizes the test for clinical use.

Next story